Document resource
Objectives To describe the clinical, histological, and therapeutic characteristics of patients with lupus nephritis (LN) and to analyze overall and class-specific remission rates in patients followed in a multidisciplinary unit.Methods A prospective, observational, single-center study was performed in patients with LN who were followed for 24 months at the multidisciplinary team in a tertiary hospital. Demographic variables, ISN/RPS class, NIH indices, treatments and disease activity parameters. Descriptive statistics were applied.Results 16 patients were included. 94% of patients were women, and the mean age at LN diagnosis was 45.3 ± 15.3 years.Six patients were Caucasian, six were Latin-American, and four were Black-African.The most frequent clinical manifestations were cutaneous (88%), articular (62%), hematological (50%), serositis (25%), and CNS involvement (6%, 1/16). ISN/RPS classes were distributed as follows: class II (25%), class III (25%), class IV (37.5%), and class V (12.5%).The most common treatment induction regimen was intravenous Methylprednisolone pulses combined with Mycophenolate Mofetil. Partial remission was achieved in 100% of patients (2.7 months) and complete remission in 75% (6.0 months). By class, complete remission rates were: II 75% (3 months), III 100% (4.5 months), IV 67% (10 months), and V 50% (24 months).Baseline protein-to-creatinine ratio (PCR) differed among classes, with higher values observed in proliferative forms. In the first months of follow-up, there was a marked reduction in PCR, which remained stable at two years (figure 1)The GFR increased from 72.5 mL/min at baseline to 90 mL/min at 3 months and remained stable thereafter. In parallel, serum creatinine decreased from 0.92 mg/dL to 0.73 mg/dL at 3 months.Complement levels increased significantly, whereas anti-dsDNA levels showed no relevant changes. The mean SLEDAI score decreased from 6 at baseline to 1 at 2 years. Serious complications were observed in 3 patients with infection at disease onset that required hospitalization and treatment with immunoglobulin therapy.Abstract PO:09:238 Figure 1Conclusions In this prospective, single-center cohort, most patients achieved rapid and sustained remission, with a significant reduction in proteinuria and stable GFR at two years. The multidisciplinary team approach enabled close follow-up and comprehensive monitoring of clinical and immunological activity, optimizing renal outcomes in LN.